Bray F, Laversanne M, Weiderpass E and Soerjomataram I: The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 127:3029–3030. 2021. View Article : Google Scholar : PubMed/NCBI

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI

Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, et al: Five-Year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: Results from the phase I KEYNOTE-001 Study. J Clin Oncol. 37:2518–2527. 2019. View Article : Google Scholar : PubMed/NCBI

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, et al: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet. 389:255–265. 2017. View Article : Google Scholar

Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, et al: Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): A randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 396:1817–1828. 2020. View Article : Google Scholar : PubMed/NCBI

Licitra L and Vermorken JB: Is there still a role for neoadjuvant chemotherapy in head and neck cancer? Ann Oncol. 15:7–11. 2004. View Article : Google Scholar

Wang H and Mao X: Evaluation of the efficacy of neoadjuvant chemotherapy for breast cancer. Drug Des Devel Ther. 14:2423–2433. 2020. View Article : Google Scholar : PubMed/NCBI

Salvà F and Felip E: Neoadjuvant chemotherapy in early-stage non-small cell lung cancer. Transl Lung Cancer Res. 2:398–402. 2013.PubMed/NCBI

Peyton CC, Tang D, Reich RR, Azizi M, Chipollini J, Pow-Sang JM, Manley B, Spiess PE, Poch MA, Sexton WJ, et al: Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for muscle-invasive bladder cancer. JAMA Oncol. 4:1535–1542. 2018. View Article : Google Scholar : PubMed/NCBI

Poggio F, Bruzzone M, Ceppi M, Pondé NF, La Valle G, Del Mastro L, de Azambuja E and Lambertini M: Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: A systematic review and meta-analysis. Ann Oncol. 29:1497–1508. 2018. View Article : Google Scholar : PubMed/NCBI

Zinner R, Johnson JM, Tuluc M, Curry JM, Luginbuhl A, Fundakowski CC, Yampolsky A, Goldman RR, Solomides CC, Mardekian S, et al: Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) outcomes in HPV(-) resectable locally advanced head and neck cancer. Ann Oncol. 31(Suppl 4): S6822020. View Article : Google Scholar

Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, Furlanetto J, Tesch H, Hanusch C, et al: A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: Clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 30:1279–1288. 2019. View Article : Google Scholar : PubMed/NCBI

Rothschild SI, Zippelius A, Eboulet EI, Savic Prince S, Betticher D, Bettini A, Früh M, Joerger M, Lardinois D, Gelpke H, et al: SAKK 16/14: Durvalumab in addition to neoadjuvant chemotherapy in patients with Stage IIIA(N2) Non-small-cell lung cancer-a multicenter single-arm phase II trial. J Clin Oncol. 39:2872–2880. 2021. View Article : Google Scholar : PubMed/NCBI

Pauken KE, Sammons MA, Odorizzi PM, Manne S, Godec J, Khan O, Drake AM, Chen Z, Sen DR, Kurachi M, et al: Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science. 354:1160–1165. 2016. View Article : Google Scholar : PubMed/NCBI

Liu J, Blake SJ, Yong MC, Harjunpää H, Ngiow SF, Takeda K, Young A, O'Donnell JS, Allen S, Smyth MJ and Teng MW: Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 6:1382–1399. 2016. View Article : Google Scholar : PubMed/NCBI

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar

Hellmann MD, Chaft JE, William WN Jr, Rusch V, Pisters KM, Kalhor N, Pataer A, Travis WD, Swisher SG and Kris MG: Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: Proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 15:e42–e50. 2014. View Article : Google Scholar : PubMed/NCBI

Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, et al: IASLC Multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy. J Thorac Oncol. 15:709–740. 2020. View Article : Google Scholar : PubMed/NCBI

Pataer A, Kalhor N, Correa AM, Raso MG, Erasmus JJ, Kim ES, Behrens C, Lee JJ, Roth JA, Stewart DJ, et al: Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 7:825–832. 2012. View Article : Google Scholar : PubMed/NCBI

Schoenfeld JD, Hanna GJ, Jo VY, Rawal B, Chen YH, Catalano PS, Lako A, Ciantra Z, Weirather JL, Criscitiello S, et al: Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: A phase 2 open-label randomized clinical trial. JAMA Oncol. 6:1563–1570. 2020. View Article : Google Scholar : PubMed/NCBI

Ferrarotto R, Bell D, Rubin ML, Hutcheson KA, Johnson JM, Goepfert RP, Phan J, Elamin YY, Torman DK, Warneke CL, et al: Impact of Neoadjuvant durvalumab with or without tremelimumab on CD8+ tumor lymphocyte density, safety, and efficacy in patients with oropharynx cancer: CIAO trial results. Clin Cancer Res. 26:3211–3219. 2020. View Article : Google Scholar : PubMed/NCBI

Uppaluri R, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, Nussenbaum B, Paniello RC, Rich JT, Jackson R, Pipkorn P, et al: Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: A multicenter, Phase II trial. Clin Cancer Res. 26:5140–5152. 2020. View Article : Google Scholar : PubMed/NCBI

Uppaluri R, Chernock R, Mansour M, Jackson R, Rich J, Pipkorn P, Paniello RC, Puram S, Zevallos JP, Annino DJ, et al: Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC). J Clinical Oncol. 39:60082021. View Article : Google Scholar

Leidner R, Crittenden M, Young K, Xiao H, Wu Y, Couey MA, Patel AA, Cheng AC, Watters AL, Bifulco C, et al: Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma. J Immunother Cancer. 9:e0024852021. View Article : Google Scholar : PubMed/NCBI

Vos JL, Elbers JBW, Krijgsman O, Traets JH, Qiao X, Leun AMV, Lubeck Y, Seignette IM, Smit LA, Willems SM, et al: Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma. Nature Commun. 12:73482021. View Article : Google Scholar

Knochelmann HM, Horton JD, Liu S, Armeson K, Kaczmar JM, Wyatt MM, Richardson MS, Lomeli SH, Xiong Y, Graboyes EM, et al: Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. Cell Rep Medicine. 2:1004262021. View Article : Google Scholar : PubMed/NCBI

Wise-Draper TM, Takiar V, Mierzwa ML, Casper K, Palackdharry S, Worden FP, Old MO, Dunlap NE, Kaczmar JM, Patil Y, et al: Association of pathological response to neoadjuvant pembrolizumab with tumor PD-L1 expression and high disease-free survival (DFS) in patients with resectable, local-regionally advanced, head and neck squamous cell carcinoma (HNSCC). J Clinical Oncol. 39:60062021. View Article : Google Scholar

Ferris RL, Spanos WC, Leidner R, Gonçalves A, Martens UM, Kyi C, Sharfman W, Chung CH, Devriese LA, Gauthier H, et al: Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. J Immunother Cancer. 9:e0025682021. View Article : Google Scholar : PubMed/NCBI

Schmid P, Salgado R, Park YH, Muñoz-Couselo E, Kim SB, Sohn J, Im SA, Foukakis T, Kuemmel S, Dent R, et al: Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: Results from the phase 1b open-label, multicohort KEYNOTE-173 study. Ann Oncol. 31:569–581. 2020. View Article : Google Scholar : PubMed/NCBI

Foldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, et al: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer. NPJ Breast Cancer. 7:92021. View Article : Google Scholar : PubMed/NCBI

Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, Telli ML, et al: Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): A randomised, double-blind, phase 3 trial. Lancet. 396:1090–1100. 2020. View Article : Google Scholar : PubMed/NCBI

Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, et al: Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 382:810–821. 2020. View Article : Google Scholar : PubMed/NCBI

Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, et al: Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: An analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 6:676–684. 2020. View Article : Google Scholar : PubMed/NCBI

Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, et al: Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer cell. 39:989–998.e5. 2021. View Article : Google Scholar : PubMed/NCBI

Yam C, Mittendorf EA, Sun R, Huo L, Damodaran S, Rauch GM, Candelaria RP, Adrada BE, Seth S, Symmans WF, et al: Neoadjuvant atezolizumab (atezo) and nab-paclitaxel (nab-p) in patients (pts) with triple-negative breast cancer (TNBC) with suboptimal clinical response to doxorubicin and cyclophosphamide (AC). J Clin Oncol. 39:5922021. View Article : Google Scholar

McArthur H, Shiao S, Karlan S, Amersi F, Arnold B, Basho R, Burnison M, Chung A, Chung C, Dang C, et al: Abstract P3-09-09: Pre-operative pembrolizumab (Pembro) with radiation therapy (RT) in patients with operable triple-negative breast cancer (TNBC). Cancer Res. 81:P3-09-092021. View Article : Google Scholar

Gianni L, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, Anton A, Zambelli S, Bianchini G, Russo S, et al: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol. 33:534–543. 2022. View Article : Google Scholar : PubMed/NCBI

Dieci MV, Guarneri V, Tosi A, Bisagni G, Musolino A, Spazzapan S, Moretti G, Vernaci GM, Griguolo G, Giarratano T, et al: Neoadjuvant chemotherapy and immunotherapy in luminal b-like breast cancer: Results of the phase II GIADA trial. Clin Cancer Res. 28:308–317. 2022. View Article : Google Scholar

Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, et al: Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 378:1976–1986. 2018. View Article : Google Scholar : PubMed/NCBI

Bott MJ, Yang SC, Park BJ, Adusumilli PS, Rusch VW, Isbell JM, Downey RJ, Brahmer JR, Battafarano R, Bush E, et al: Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 158:269–276. 2019. View Article : Google Scholar : PubMed/NCBI

Reuss JE, Anagnostou V, Cottrell TR, Smith KN, Verde F, Zahurak M, Lanis M, Murray JC, Chan HY, McCarthy C, et al: Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. J Immunother Cancer. 8:e0012822020. View Article : Google Scholar : PubMed/NCBI

Bar J, Urban D, Ofek E, Ackerstein A, Redinsky I, Golan N, Kamer I, Simansky D, Onn A, Raskin S, et al: Neoadjuvant pembrolizumab (Pembro) for early stage non-small cell lung cancer (NSCLC): Updated report of a phase i study, MK3475-223. J Clin Oncol. 37:8534. 2019. View Article : Google Scholar

Shu CA, Gainor JF, Awad MM, Chiuzan C, Grigg CM, Pabani A, Garofano RF, Stoopler MB, Cheng SK, White A, et al: Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: An open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 21:786–795. 2020. View Article : Google Scholar : PubMed/NCBI

Provencio M, Nadal E, Insa A, García-Campelo MR, Casal-Rubio J, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, De Castro, Carpeño J, et al: Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): An open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 21:1413–1422. 2020. View Article : Google Scholar : PubMed/NCBI

Gao S, Li N, Gao S, Xue Q, Ying J, Wang S, Tao X, Zhao J, Mao Y, Wang B, et al: Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 15:816–826. 2020. View Article : Google Scholar : PubMed/NCBI

Besse B, Adam J, Cozic N, Chaput N, Planchard D, Mezquita L, Mezquita JR, Mezquita P, Mezquita C, Mezquita A, et al: 1215O-SC Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial. Ann Oncol. 31(Suppl): S794–S795. 2020. View Article : Google Scholar

Lee J, Chaft J, Nicholas A, Patterson A, Waqar S, Toloza E, Haura E, Raz D, Reckamp K, Merritt R, et al: PS01.05 Surgical and clinical outcomes with neoadjuvant Atezolizumab in resectable stage IB-IIIB NSCLC: LCMC3 trial primary analysis. J Thorac Oncol. 16(Suppl): S59–S61. 2021. View Article : Google Scholar

Zhao ZR, Yang CP, Chen S, Yu H, Lin YB, Lin YB, Qi H, Jin JT, Lian SS, Wang YZ, et al: Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer. Oncoimmunology. 10:19960002021. View Article : Google Scholar : PubMed/NCBI

Eichhorn F, Klotz LV, Kriegsmann M, Bischoff H, Schneider MA, Muley T, Kriegsmann K, Haberkorn U, Heussel CP, Savai R, et al: Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience. Lung Cancer. 153:150–157. 2021. View Article : Google Scholar : PubMed/NCBI

Cascone T, William WN Jr, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, et al: Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: The phase 2 randomized NEOSTAR trial. Nat Med. 27:504–514. 2021. View Article : Google Scholar : PubMed/NCBI

Altorki NK, McGraw TE, Borczuk AC, Saxena A, Port JL, Stiles BM, Lee BE, Sanfilippo NJ, Scheff RJ, Pua BB, et al: Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: A single-centre, randomised phase 2 trial. Lancet Oncol. 22:824–835. 2021. View Article : Google Scholar : PubMed/NCBI

Tong BC, Gu L, Wang X, Wigle DA, Phillips JD, Harpole DH Jr, Klapper JA, Sporn T, Ready NE, D'Amico TA, et al: Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 163:427–436. 2022. View Article : Google Scholar

Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, et al: Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 386:1973–1985. 2022. View Article : Google Scholar : PubMed/NCBI

Gu Y, Chen X, Wang D, Ding M, Xue L, Zhen F, Xu J, Wang M, Li Y, Sun N, et al: 175P A study of neoadjuvant sintilimab combined with triplet chemotherapy of lipo-paclitaxel, cisplatin, and S-1 for resectable esophageal squamous cell carcinoma (ESCC). Ann Oncol. 31(Suppl 6): S1307–S1308. 2020. View Article : Google Scholar

Li H, Li C, Zheng Y, Zhao S, Chen X, Han Y, Xiang J and Wu Y: Preoperative combination of pembrolizumab with chemoradiation for patients with locally advanced esophageal squamous cell carcinoma: Mid-term results of NCT03604991. Dis Esophagus. 33:2020 View Article : Google Scholar

Li C, Zhao S, Zheng Y, Han Y, Chen X, Cheng Z, Wu Y, Feng X, Qi W, Chen K, et al: Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1). Eur J Cancer. 144:232–241. 2021. View Article : Google Scholar

van den Ende T, de Clercq NC, van Berge Henegouwen MI, Gisbertz SS, Geijsen ED, Verhoeven RHA, Meijer SL, Schokker S, Dings MPG, Bergman JJGHM, et al: Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: A single-arm phase ii feasibility trial (PERFECT). Clin Cancer Res. 27:3351–3359. 2021. View Article : Google Scholar : PubMed/NCBI

Zhang Z, Hong ZN, Xie S, Lin W, Lin Y, Zhu J, Yang X, Lin Z, Lin J and Kang M: Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: A single-arm, single-center, phase 2 trial (ESONICT-1). Ann Transl Med. 9:16232021. View Article : Google Scholar : PubMed/NCBI

Xing W, Zhao L, Zheng Y, Liu B, Liu X, Li T, Zhang Y, Ma B, Yang Y, Shang Y, et al: The Sequence of chemotherapy and toripalimab might influence the efficacy of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell Cancer-A phase ii study. Front Immunol. 12:7724502021. View Article : Google Scholar : PubMed/NCBI

Wang Z: Neoadjuvant camrelizumab combined with chemotherapy and apatinib for locally advanced thoracic esophageal squamous cell carcinoma (ESCC): A single-arm, open-label, phase Ib study. J Clin Oncol. 39:4047. 2021. View Article : Google Scholar

Xu W, Jiang Y, Wang C, Wu J, Li J, Hu Y, Lu W, Shen D, Wang Y and Chen Q: The efficacy and safety of neoadjuvant camrelizumab and chemotherapy for locally advanced thoracic esophageal squamous cell carcinoma. J Clin Oncol. 40(Suppl 4): S2782022. View Article : Google Scholar

Liu J, Li J, Lin W, Shao D, Depypere L, Zhang Z, Li Z, Cui F, Du Z, Zeng Y, et al: Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study. Int J Cancer. 151:128–137. 2022. View Article : Google Scholar : PubMed/NCBI

He W, Leng X, Mao T, Luo X, Zhou L, Yan J, Peng L, Fang Q, Liu G, Wei X, et al: Toripalimab plus paclitaxel and carboplatin as neoadjuvant therapy in locally advanced resectable esophageal squamous cell carcinoma. Oncologist. 27:e18–e28. 2022. View Article : Google Scholar : PubMed/NCBI

Liu J, Yang Y, Liu Z, Fu X, Cai X, Li H, Zhu L, Shen Y, Zhang H, Sun Y, et al: Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. J Immunother Cancer. 10:e0042912022. View Article : Google Scholar : PubMed/NCBI

Kelly RJ, Smith KN, Anagnostou V, Thompson E, Hales RK, James Battafarano RJ, Voong KR, Yang SC, Feliciano JL, Shin EJ, et al: Neoadjuvant nivolumab plus concurrent chemoradiation in stage II/III esophageal/gastroesophageal junction cancer. J Clin Oncol. 37:1422019. View Article : Google Scholar

Liu Y, Han G, Li H, Zhao Y, Zhuang J, Wang G, Li B, Wang J, Li Z, Xia Q, et al: Camrelizumab combined with FOLFOX as neoadjuvant therapy for resectable locally advanced gastric and gastroesophageal junction adenocarcinoma. J Clin Oncol. 38:45362020. View Article : Google Scholar

Shah MA, Almhanna K, Iqbal S, Thakkar P, Schneider BJ, Yantiss R, Wu Y, Futamura E, Port JL, Spinelli C, et al: Multicenter, randomized phase II study of neoadjuvant pembrolizumab plus chemotherapy and chemoradiotherapy in esophageal adenocarcinoma (EAC). J Clin Oncol. 39:40052021. View Article : Google Scholar

Sun W, Saeed A, Al-Rajabi RMT, Kasi A, Veeramachaneni NK, Al-Kasspooles MM, Baranda JC, Phadnis M, Godwin AK, Olyaee M, et al: A phase II study of perioperative mFOLFOX chemotherapy plus pembrolizumab combination in patients with potentially resectable adenocarcinoma of the esophageal, gastroesophageal junction (GEJ), and stomach. J Clin Oncol. 40:3292022. View Article : Google Scholar

Tao K, Yin Y, Lin Y, Li W, Li R, Liu W, Xiong Z, Zeng X, Cai M, Wu C and Zhang P: Neoadjuvant PD-1 inhibitor tislelizumab combined with s-1 plus oxaliplatin in patients with local advanced gastric cancer or gastroesophageal junction adenocarcinoma: Interim results of a single-arm, phase II trial. J Clin Oncol. 40:3002022. View Article : Google Scholar

Jiang H, Yu X, Li N, Kong M, Ma Z, Zhou D, Wang W, Wang H, Wang H, He K, et al: Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: Early results of a phase 2 study. J Immunother Cancer. 10:e0036352022. View Article : Google Scholar : PubMed/NCBI

Ho WJ, Zhu Q, Durham J, Popovic A, Xavier S, Leatherman J, Mohan A, Mo G, Zhang S, Gross N, et al: Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity. Nat Cancer. 2:891–903. 2021. View Article : Google Scholar : PubMed/NCBI

Su Y, Lin Y, Hsiao C, Ou D, Chen S, Wu Y, Lee W, Lin J, Hsu C, Ho M, et al: P-124 Nivolumab plus ipilimumab as neoadjuvant therapy for potentially resectable hepatocellular carcinoma. Ann Oncol. 32(Suppl): S1412021. View Article : Google Scholar

Kaseb AO, Hasanov E, Cao HST, Xiao L, Vauthey JN, Lee SS, Yavuz BG, Mohamed YI, Qayyum A, Jindal S, et al: Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: A randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 7:208–218. 2022. View Article : Google Scholar : PubMed/NCBI

Marron TU, Fiel MI, Hamon P, Fiaschi N, Kim E, Ward SC, Zhao Z, Kim J, Kennedy P, Gunasekaran G, et al: Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: A single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 7:219–229. 2022. View Article : Google Scholar : PubMed/NCBI

Gao J, Karam JA, Tannir NM, Campbell MT, Tidwell RS, Ahrar K, Rao P, Ng CS, Jonasch E, Matin SF, et al: A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx). J Clin Oncol. 37:45012019. View Article : Google Scholar

Karam JA, Msaouel P, Matin SF, Campbell MT, Zurita AJ, Shah AY, Wistuba II, Haymaker CL, Marmonti E, Duose DY, et al: A phase II study of sitravatinib (Sitra) in combination with nivolumab (Nivo) in patients (Pts) undergoing nephrectomy for locally-advanced clear cell renal cell carcinoma (accRCC). J Clin Oncol. 39:3122021. View Article : Google Scholar

Gorin MA, Patel HD, Rowe SP, Hahn NM, Hammers HJ, Pons A, Trock BJ, Pierorazio PM, Nirschl TR, Salles DC, et al: Neoadjuvant nivolumab in patients with high-risk nonmetastatic renal cell carcinoma. Eur Urol Oncol. 5:113–117. 2022. View Article : Google Scholar :

Bex A, Abu-Ghanem Y, Thienen JVV, Graafland N, Lagerveld B, Zondervan P, Beerlage H, van Moorselaar J, Kockx M, Van Dam PJ, et al: Efficacy, safety, and biomarker analysis of neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx). J Clin Oncol. 40:2892022. View Article : Google Scholar

Carlo MI, Attalla K, Mazaheri Y, Gupta S, Yildirim O, Murray SJ, Coskey DT, Kotecha R, Lee CH, Feldman DR, et al: Phase II study of neoadjuvant nivolumab in patients with locally advanced clear cell renal cell carcinoma undergoing nephrectomy. Eur Urology. 81:570–573. 2022. View Article : Google Scholar

Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K, Lopez-Yurda M, Grootscholten C, Beets GL, Snaebjornsson P, et al: Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 26:566–576. 2020. View Article : Google Scholar : PubMed/NCBI

Yuki S, Bando H, Tsukada Y, Inamori K, Komatsu Y, Homma S, Uemura M, Kato T, Kotani D, Fukuoka F, et al: SO-37 Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stability and microsatellite instability-high, locally advanced rectal cancer (EPOC 1504). Ann Oncol. 31:S230–S231. 2020. View Article : Google Scholar

Avallone A, De Stefano A, Pace U, Catteau A, Di Gennaro E, Tatangelo F, Boquet I, Cassata A, Costantini S, De Franciscis S, et al: 491P Neoadjuvant nivolumab in early stage colorectal cancer. Ann Oncol. 31(Suppl 4): S4492020. View Article : Google Scholar

Rahma OE, Yothers G, Hong TS, Russell MM, You YN, Parker W, Jacobs SA, Colangelo LH, Lucas PC, Gollub MJ, et al: Use of total neoadjuvant therapy for locally advanced rectal cancer: Initial results from the pembrolizumab arm of a phase 2 randomized clinical trial. JAMA Oncol. 7:1225–1230. 2021. View Article : Google Scholar : PubMed/NCBI

Salvatore L, Bensi M, Corallo S, Bergamo F, Pellegrini I, Rasola C, Borelli B, Tamburini E, Randon G, Galuppo S, et al: O-12 Phase II study of preoperative chemoradiotherapy plus avelumab in patients with locally advanced rectal cancer: The AVANA study. Ann Oncol. 32(Suppl 3): S2232021. View Article : Google Scholar

Tamberi S, Grassi E, Corbelli J, Papiani G, Barbera MA, Zingaretti C, Moretti CC, Montroni I, Petracci E, Caruso D, et al: A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study first-stage (NCT04083365). Tumori. 107:92–93. 2021.

Shamseddine A, Zeidan Y, Bouferraa Y, Turfa R, Kattan J, Mukherji D, Temraz S, Alqasem K, Amarin R, Al Awabdeh T, et al: Efficacy and safety of neoadjuvant short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma: Averectal study. Ann Oncol. 32(Suppl): S2152021. View Article : Google Scholar

Carrasco J, Schröder D, Sinapi I, De Cuyper A, Beniuga G, Delmarcelle S, van Laethem JL, Huyghe N, Bar I, Hendlisz A, et al: 397P R-IMMUNE interim analysis: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with localized rectal cancer. Ann Oncol. 32(Suppl 5): S5372021. View Article : Google Scholar

Hu H, Kang L, Zhang J, Wu Z, Wang H, Huang M, Lan P, Wu X, Wang C, Cao W, et al: Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): A single-centre, parallel-group, non-comparative, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 7:38–48. 2022. View Article : Google Scholar

Necchi A, Raggi D, Gallina A, Madison R, Colecchia M, Lucianò R, Montironi R, Giannatempo P, Farè E, Pederzoli F, et al: Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with Muscle-invasive bladder carcinoma with variant histologies. Eur Urol. 77:439–446. 2020. View Article : Google Scholar

Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF, Gravis G, Herranz UA, et al: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med. 25:1706–1714. 2019. View Article : Google Scholar : PubMed/NCBI

Szabados B, Rodriguez-Vida A, Durá I, Crabb SJ, Van Der Heijden MS, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, et al: Toxicity and surgical complication rates of neoadjuvant atezolizumab in patients with Muscle-invasive bladder cancer undergoing radical cystectomy: Updated safety results from the ABACUS trial. Eur Urol Oncol. 4:456–463. 2021. View Article : Google Scholar : PubMed/NCBI

Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, et al: Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 26:1845–1851. 2020. View Article : Google Scholar : PubMed/NCBI

Wei XX, McGregor BA, Lee RJ, Gao X, Kilbridge KL, Preston MA, Mossanen M, Ingham MD, Steele GS, Klein A, et al: Durvalumab as neoadjuvant therapy for muscle-invasive bladder cancer: Preliminary results from the Bladder Cancer Signal Seeking Trial (BLASST)-2. J Clin Oncol. 38:507. 2020. View Article : Google Scholar

Grande E, Guerrero F, Puente J, Galante I, Duran I, Dominguez M, Gordoa TA, Burgos J, Font A, Pinto A, et al: DUTRENEO Trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature. J Clin Oncol. 38:50122020. View Article : Google Scholar

Rodriguez-Moreno JF, de Velasco G, Alvarez-Fernandez C, Collado R, Fernandez-Rodriguez R, Vazquez Estevez S, Virizuela Echaburu JA, Gajate Borau P, Font A, Lainez N, et al: 761P Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer. NEODURVARIB trial. Ann Oncol. 31(Suppl 4): S5892020. View Article : Google Scholar

Hoimes CJ, Adra N, Fleming MT, Kaimakliotis HZ, Picus J, Smith ZL, Walling R, Alter RS, Kassar M, Wang J, et al: Phase Ib/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): Final results from the cisplatin (C)-eligible cohort of HCRN GU14-188. J Clin Oncol. 38:50472020. View Article : Google Scholar

Kaimakliotis HZ, Adra N, Kelly WK, Trabulsi EJ, Lauer RC, Picus J, Smith ZL, Walling R, Masterson TA, Adra N, et al: Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of. GU14–188. J Clin Oncol. 38:50192020. View Article : Google Scholar

van Dijk N, Gil-Jimenez A, Silina K, Hendricksen K, Smit LA, de Feijter JM, van Montfoort ML, van Rooijen C, Peters D, Broeks A, et al: Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: The NABUCCO trial. Nat Med. 26:1839–1844. 2020. View Article : Google Scholar : PubMed/NCBI

Van Dorp J, Suelmann BBM, Mehra N, Van Montfoort M, Van Dijk N, Hendricksen K, de Feijter J, Boellaard T, Daletzakis A, Blank CU, et al: LBA31 High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advanced urothelial cancer (NABUCCO cohort 2). Ann Oncol. 32(Suppl 5): S1305–S1306. 2021. View Article : Google Scholar

Natesan DV, Zhang L, Oh DY, Porten SP, Meng M, Pruthi R, Cooperberg MR, Carroll P, Chou J, Borno H, et al: Updated results of phase II trial using escalating doses of neoadjuvant atezolizumab for cisplatin-ineligible patients with nonmetastatic urothelial cancer (NCT02451423). J Clin Oncol. 39:e165102021. View Article : Google Scholar

Grivas P, Yin J, Koshkin VS, Cole S, Jain RK, Dreicer R, Cetnar JP, Sundi D, Gartrell BA, Galsky MD, et al: PrE0807: A phase Ib feasibility trial of neoadjuvant nivolumab (N) without or with lirilumab (L) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC). J Clin Oncol. 39:45182021. View Article : Google Scholar

Cathomas R, Rothschild S, Hayoz S, Spahn M, Schardt J, Seiler R, Erdmann A, Aeppli S, Mach N, Strebel R, et al: Safety and efficacy of perioperative cisplatin/gemcitabine (cis/gem) and durvalumab (durva) for operable muscle-invasive urothelial carcinoma (MIUC): SAKK 06/17. J Clin Oncol. 39:4302021. View Article : Google Scholar

Rose TL, Harrison MR, Deal AM, Ramalingam S, Whang YE, Brower B, Dunn M, Osterman CK, Heiling HM, Bjurlin MA, et al: Phase II study of gemcitabine and Split-Dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer. J Clin Oncol. 39:3140–3148. 2021. View Article : Google Scholar : PubMed/NCBI

Funt SA, Lattanzi M, Whiting K, Al-Ahmadie H, Quinlan C, Teo MY, Lee CH, Aggen D, Zimmerman D, McHugh D, et al: Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: A multicenter, Single-Arm, phase II trial. J Clin Oncol. 40:1312–1322. 2022. View Article : Google Scholar : PubMed/NCBI

Blank CU, Rozeman EA, Fanchi LF, Sikorska K, van de Wiel B, Kvistborg P, Krijgsman O, van den Braber M, Philips D, Broeks A, et al: Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 24:1655–1661. 2018. View Article : Google Scholar : PubMed/NCBI

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, et al: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 24:1649–1654. 2018. View Article : Google Scholar : PubMed/NCBI

Amaria RN, Postow MA, Tetzlaff MT, Ross MI, Glitza IC, McQuade JL, Wong MKK, Gershenwald JE, Goepfert R, Keung EJY, et al: Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma. J Clin Oncol. 39:9502. 2021. View Article : Google Scholar

Rozeman EA, Menzies AM, van Akkooi ACJ, Adhikari C, Bierman C, van de Wiel BA, Scolyer RA, Krijgsman O, Sikorska K, Eriksson H, et al: Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): A multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 20:948–960. 2019. View Article : Google Scholar : PubMed/NCBI

Huang AC, Xu X, Orlowski RJ, George SM, Chilukuri L, Kozlov A, Carberry M, Giles L, McGettigan S, Kreider K, et al: Abstract CT181: Safety, activity, and biomarkers for neoadjuvant anti- PD-1 therapy in melanoma. Cancer Res. 78:CT181. 2018. View Article : Google Scholar

Huang AC, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, Manne S, Kraya AA, Wubbenhorst B, Dorfman L, et al: A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 25:454–461. 2019. View Article : Google Scholar : PubMed/NCBI

Wang X, Cui C, Si L, Li C, Dai J, Mao L, Bai X, Chi J, Sheng X, Kong Y, et al: A phase Ib clinical trial of neoadjuvant OrienX010, an oncolytic virus, in combination with toripalimab in patients with resectable stage IIIb to stage IVM1a acral melanoma. J Clin Oncol. 39:9570. 2021. View Article : Google Scholar

Hyngstrom JR, Holmen S, Andtbacka RH, William B, Tanaka M, Gravley W, David B, Hu-Lieskovan S and Van Brocklin M: Neoadjuvant Canerpaturev (C-REV) Oncolytic Immunotherapy in Combination with Nivolumab (Nivo) in Resectable Advanced Melanoma. Pigment. Cell Melanoma Res. 35:1802022.

Cocorocchio E, Nezi L, Gandini S, Manzo T, Mazzarella L, Lotti F, Pala L, Gnagnarella P, Conforti F, Pennacchioli E, et al: 1072P Primary ipilimumab/nivolumab immunotherapy followed by adjuvant nivolumab in patients with locally advanced or oligometastatic melanoma: Update on outcome. Ann Oncol. 32:S889–S890. 2021. View Article : Google Scholar

Najjar YG, McCurry D, Lin H, Lin Y, Zang Y, Davar D, Karunamurthy A, Drabick JJ, Neves RI, Butterfield LH, et al: Neoadjuvant pembrolizumab and High-dose IFNα-2b in resectable regionally advanced melanoma. Clin Cancer Res. 27:4195–4204. 2021. View Article : Google Scholar : PubMed/NCBI

Topalian SL, Bhatia S, Amin A, Kudchadkar RR, Sharfman WH, Lebbé C, Delord JP, Dunn LA, Shinohara MM, Kulikauskas R, et al: Neoadjuvant nivolumab for patients with resectable merkel cell carcinoma in the CheckMate 358 trial. J Clin Oncol. 38:2476–2487. 2020. View Article : Google Scholar : PubMed/NCBI

Fisher B, Gunduz N, Coyle J, Rudock C and Saffer E: Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res. 49:1996–2001. 1989.PubMed/NCBI

Fisher B, Saffer E, Rudock C, Coyle J and Gunduz N: Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice. Cancer Res. 49:2002–2004. 1989.PubMed/NCBI

Bracci L, Schiavoni G, Sistigu A and Belardelli F: Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 21:15–25. 2014. View Article : Google Scholar

Wei SC, Duffy CR and Allison JP: Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8:1069–1086. 2018. View Article : Google Scholar : PubMed/NCBI

Waser NA, Adam A, Schweikert B, Vo L, McKenna M, Breckenridge M, Penrod JR and Goring S: Pathologic response as early endpoint for survival following neoadjuvant therapy (NEO-AT) in resectable non-small cell lung cancer (rNSCLC): Systematic literature review and meta-analysis. Ann Oncol. 31(Suppl 4): S744–S753. 2020. View Article : Google Scholar

Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, et al: Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet. 384:164–172. 2014. View Article : Google Scholar : PubMed/NCBI

Menzies AM, Amaria RN, Rozeman EA, Huang AC, Tetzlaff MT, van de Wiel BA, Lo S, Tarhini AA, Burton EM, Pennington TE, et al: Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med. 27:301–309. 2021. View Article : Google Scholar : PubMed/NCBI

Chaft JE, Hellmann MD, Velez MJ, Travis WD and Rusch VW: Initial experience with lung cancer resection after treatment with T-cell checkpoint inhibitors. Ann Thorac Surg. 104:e217–e218. 2017. View Article : Google Scholar : PubMed/NCBI

Bott MJ, Cools-Lartigue J, Tan KS, Dycoco J, Bains MS, Downey RJ, Huang J, Isbell JM, Molena D, Park BJ, et al: Safety and feasibility of lung resection after immunotherapy for metastatic or unresectable tumors. Ann Thorac Surg. 106:178–183. 2018. View Article : Google Scholar : PubMed/NCBI

du Bois H, Heim TA and Lund AW: Tumor-draining lymph nodes: At the crossroads of metastasis and immunity. Sci Immunol. 6. pp. eabg35512021, View Article : Google Scholar

Fear VS, Forbes CA, Neeve SA, Fisher SA, Chee J, Waithman J, Ma SK, Lake R, Nowak AK, Creaney J, et al: Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used. Cancer Immunol Immunother. 70:3249–3258. 2021. View Article : Google Scholar : PubMed/NCBI

Fransen MF, Arens R and Melief CJM: Local targets for immune therapy to cancer: Tumor draining lymph nodes and tumor microenvironment. Int J Cancer. 132:1971–1976. 2013. View Article : Google Scholar

Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, et al: Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: Results from the IMMUNOTARGET registry. Ann Oncol. 30:1321–1328. 2019. View Article : Google Scholar : PubMed/NCBI

Lee CK, Man J, Lord S, Links M, Gebski V, Mok T and Yang JC: Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis. J Thorac Oncol. 12:403–407. 2017. View Article : Google Scholar

To KKW, Fong W and Cho WCS: Immunotherapy in treating EGFR-mutant lung cancer: Current challenges and new strategies. Front Oncol. 11:6350072021. View Article : Google Scholar : PubMed/NCBI

Zhang C, Chen HF, Yan S, Wu L, Yan LX, Yan XL, Yue DS, Xu CW, Zheng M, Li JS, et al: Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multi-center pooled analysis. NPJ Precis Oncol. 6:662022. View Article : Google Scholar

Liu J, O'Donnell JS, Yan J, Madore J, Allen S, Smyth MJ and Teng MWL: Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome. Oncoimmunology. 8:e15815302019. View Article : Google Scholar : PubMed/NCBI